Alcon Publishes Agenda for 2025 Annual General Meeting
Alcon welcomes its shareholders to its third in-person AGM
Alcon Board of Directors proposes to elect Deborah Di Sanzo as a new Board member
Proposed dividend of CHF 0.28 cash per share
GENEVA, April 04, 2025--(BUSINESS WIRE)--Regulatory News:
Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 6, 2025.
Alcon is pleased to welcome shareholders to its third in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting.
Alcon's Board of Directors proposes to the AGM to elect Deborah Di Sanzo as a new Board member. An innovative business leader with more than thirty years of experience in the fields of technology and health care, Ms. Di Sanzo brings to the Board extensive experience in digital, artificial intelligence, and the use of cutting-edge technology and healthcare insights to create effective and innovative solutions. Ms. Di Sanzo has served as president of Best Buy Health for Best Buy Co. Inc. since 2020, where she is responsible for the company's health technology business focused on enabling care at home for everyone. She is also an instructor at the Harvard T.H. Chan School of Public Health and has served on the board of AstraZeneca since 2017.
After three years of service to Alcon, Board member Raquel C. Bono, M.D., has decided not to stand for re-election to the Board. All other members of the Board will stand for re-election. "On behalf of Alcon and our entire Board, I'd like to thank Dr. Bono for her contributions to Alcon's success during her term as a Member of the Board the past three years," said Mike Ball, Chair of the Alcon Board.
The invitation to the AGM, including explanatory information on individual agenda items, will be published in the Swiss Gazette of Commerce on April 4, 2025, and will be available, together with the Say-on-Pay brochure, the 2024 Annual Report, the 2024 Report on Non-Financial Matters and additional related material, online at https://investor.alcon.com/news-and-events/events-and-presentations/event-details/2025/2025-Annual-General-Meeting-2025-z3OE4BbV8t/default.aspx.
Agenda for Alcon's AGM
1. Approval of the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2024
2. Discharge of the members of the Board of Directors and the members of the Executive Committee
3. Appropriation of earnings and declaration of dividend as per the balance sheet of Alcon Inc. of December 31, 2024
If approved by the shareholders, a gross dividend of CHF 0.28 in cash per share will be payable with the first trading day ex-dividend expected to be May 13, 2025 (for shares held through SIX SIS) and May 14, 2025 (for shares held through DTC), the record date expected to be May 14, 2025, and the payout date in Switzerland expected to be on or around May 15, 2025. The Swiss withholding tax of 35% will be deducted from the gross dividend amount. The different ex-dividend dates for shares held through SIX SIS and through DTC are due to the fact that the US settlement practice changed from T+2 to T+1 in 2024.
4. Consultative vote on the 2024 Report on Non Financial Matters
5. Votes on the compensation of the Board of Directors and of the Executive Committee
5.1 Consultative vote on the 2024 Compensation Report
5.2 Binding vote on the maximum aggregate amount of compensation of the Board of Directors for the next term of office, i.e. from the 2025 Annual General Meeting to the 2026 Annual General Meeting
5.3 Binding vote on the maximum aggregate amount of compensation of the Executive Committee for the following financial year, i.e., 2026
6. Re-election and Election of the Chair and the Members of the Board of Directors
6.1 Re-election of F. Michael Ball (as Member and Chair)
6.2 Re-election of Lynn D. Bleil (as Member)
6.3 Re-election of Arthur Cummings (as Member)
6.4 Re-election of David J. Endicott (as Member)
6.5 Re-election of Thomas Glanzmann (as Member)
6.6 Re-election of D. Keith Grossman (as Member)
6.7 Re-election of Scott Maw (as Member)
6.8 Re-election of Karen May (as Member)
6.9 Re-election of Ines Pöschel (as Member)
6.10 Re-election of Dieter Spälti (as Member)
6.11 Election of Deborah Di Sanzo (as Member), effective September 1, 2025
7. Re-election of the Members of the Compensation Committee
7.1 Re-election of Thomas Glanzmann
7.2 Re-election of Scott Maw
7.3 Re-election of Karen May
7.4 Re-election of Ines Pöschel
8. Re-election of the independent representative
9. Re-election of the statutory auditors
Cautionary Note Regarding Forward-Looking Statements
This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our liquidity, revenue, gross margin, operating margin, effective tax rate, foreign currency exchange movements, earnings per share, our plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such as our market growth assumptions, our social impact and sustainability plans, targets, goals and expectations, and generally, our expectations concerning our future performance.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict such as: cybersecurity breaches or other disruptions of our information technology systems; our ability to effectively manage the risks associated with the ethical use of disruptive technologies; compliance with data privacy, identity protection and information security laws, particularly with the increased use of artificial intelligence; the impact of a disruption in our global supply chain, including the effect of tariffs, or important facilities, particularly when we single-source or rely on limited sources of supply; our ability to manage social impact and sustainability matters; our reliance on outsourcing key business functions; global and regional economic, financial, monetary, legal, tax, political and social change; the increasingly challenging economic, political and legal environment in China; terrorism, war and other resulting events such as economic sanctions and trade restrictions; our ability to manage the risks associated with operating as a third party contract manufacturer; our ability to forecast sales demand and manage our inventory levels and the changing buying patterns of our customers; our success in completing and integrating strategic acquisitions, including equity investments in early-stage companies; the success of our research and development efforts, including our ability to innovate to compete effectively; our ability to comply with the US Foreign Corrupt Practices Act of 1977 and other applicable anti-corruption laws; pricing pressure from changes in third party payor coverage and reimbursement methodologies; our ability to properly educate and train healthcare providers on our products; our ability to protect our intellectual property; our ability to comply with all laws to which we may be subject; the ability to obtain regulatory clearance and approval of our products as well as compliance with any post-approval obligations, including quality control of our manufacturing; the effect of product recalls or voluntary market withdrawals; the accuracy of our accounting estimates and assumptions, including pension and other post-employment benefit plan obligations and the carrying value of intangible assets; the impact of unauthorized importation of our products from countries with lower prices to countries with higher prices; our ability to service our debt obligations; the need for additional financing through the issuance of debt or equity; the effects of litigation, including product liability lawsuits and governmental investigations; supply constraints and increases in the cost of energy; our ability to attract and retain qualified personnel; legislative, tax and regulatory reform; the impact of being listed on two stock exchanges; the ability to declare and pay dividends; the different rights afforded to our shareholders as a Swiss corporation compared to a US corporation; the effect of maintaining or losing our foreign private issuer status under US securities laws; and the ability to enforce US judgments against Swiss corporations.
Additional factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this document speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
Connect with us onFacebook LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403880515/en/
Contacts
Investor Relations Daniel CravensAllen Trang+ 41 589 112 110 (Geneva)+ 1 817 615 2789 (Fort Worth)investor.relations@alcon.com
Media Relations Steven Smith+ 41 589 112 111 (Geneva)+ 1 817 551 8057 (Fort Worth)globalmedia.relations@alcon.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
The Dollar Is Crumbling, And Hedge Fund Analyst Says A New Global Trade Is Brewing
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. As the U.S. dollar has slumped to its lowest level in over two years, emerging market stocks rallied in near-perfect inverse fashion—a trend that may be just at its early stages. The iShares MSCI Emerging Markets ETF (NYSE:EEM), which holds more than 800 EM stocks, posted its ninth consecutive daily gain—the longest streak since the fund's inception in 2016—reaching levels last seen before Russia's invasion of Ukraine. 'As an investor, I want to operate under the assumption that... the dollar is going to be devaluing," Otavio Costa, macro analyst at Crescat Capital, said in an exclusive interview with Benzinga. "You want to buy natural resources, you want to buy hard assets, but you also want to buy emerging markets in a big way,' he added. Trending: Let your money work smarter: . No hidden fees, no commitment. At the core of Costa's view is the widening gap in interest payments between the U.S. and its developed peers. The U.S. spends about 5% of its gross domestic product on interest—when combining federal and local levels—far exceeding developed peers like Germany, Japan, and Canada, where interest costs are about 1%. Because the U.S. has far less fiscal flexibility, Costa believes it will be forced to cut rates more aggressively than other economies. For Costa, the implication is clear: 'That's going to translate into interest rates differentials contracting and causing the dollar to fall."Costa emphasized the valuation gap between U.S. and emerging market equities. "The Cyclically Adjusted Price-to-Earnings (CAPE) ratio of the U.S. is about 35, one of the highest in history. You look at Brazil, and it's about 12." he said. "Why would you not deploy capital there?' Costa sees emerging markets, hard assets and undervalued foreign equities as the likely beneficiaries of this rotation. He sees particular value in Brazil, not just in equities but in fixed income as well. "In Brazil, the equity market looks attractive, the bond market looks very attractive," Costa said. Among developed markets, Costa is particularly bullish on Canada. He sees the Canadian dollar—historically linked to oil and natural gas—on the verge of a breakout, fueled by its commodity exposure and underweight positioning in global portfolios. "The Canadian dollar is a contrarian play that could benefit from U.S. weakness and commodity strength," he said, adding that Canadian mining companies could also enjoy capital inflows. He added that capital markets are already signaling a shift. "Argentina starts doing well all of a sudden after politics changes... India is doing quite well. Japanese equities doing better than the U.S. Now you're seeing European equities outperform U.S. equities." "These things are just starting to occur," he said. "They're big moves." Read Next: Level up your portfolio tracking with Snowball Analytics: see all your investments in one dashboard with real-time stock and dividend tracking for free today. Image created using artificial intelligence via Midjourney. This article The Dollar Is Crumbling, And Hedge Fund Analyst Says A New Global Trade Is Brewing originally appeared on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
41 minutes ago
- Yahoo
One Booz Allen Hamilton Holding Insider Raised Their Stake In The Previous Year
Insiders were net buyers of Booz Allen Hamilton Holding Corporation's (NYSE:BAH ) stock during the past year. That is, insiders bought more stock than they sold. While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. The Independent Director Joan Lordi Amble made the biggest insider purchase in the last 12 months. That single transaction was for US$294k worth of shares at a price of US$147 each. That means that even when the share price was higher than US$103 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Joan Lordi Amble was the only individual insider to buy shares in the last twelve months. Joan Lordi Amble purchased 3.62k shares over the year. The average price per share was US$143. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! View our latest analysis for Booz Allen Hamilton Holding There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It's great to see that Booz Allen Hamilton Holding insiders own 1.6% of the company, worth about US$209m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. It would be great to see more insider buying, but overall it seems like Booz Allen Hamilton Holding insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Our analysis shows 3 warning signs for Booz Allen Hamilton Holding (1 is a bit unpleasant!) and we strongly recommend you look at these before investing. But note: Booz Allen Hamilton Holding may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
EQT Corporation's (NYSE:EQT) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Most readers would already be aware that EQT's (NYSE:EQT) stock increased significantly by 12% over the past three months. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement. Particularly, we will be paying attention to EQT's ROE today. ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for EQT is: 1.9% = US$454m ÷ US$24b (Based on the trailing twelve months to March 2025). The 'return' refers to a company's earnings over the last year. One way to conceptualize this is that for each $1 of shareholders' capital it has, the company made $0.02 in profit. View our latest analysis for EQT So far, we've learned that ROE is a measure of a company's profitability. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics. It is hard to argue that EQT's ROE is much good in and of itself. Not just that, even compared to the industry average of 13%, the company's ROE is entirely unremarkable. In spite of this, EQT was able to grow its net income considerably, at a rate of 47% in the last five years. We reckon that there could be other factors at play here. Such as - high earnings retention or an efficient management in place. Next, on comparing with the industry net income growth, we found that EQT's growth is quite high when compared to the industry average growth of 37% in the same period, which is great to see. The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is EQT fairly valued compared to other companies? These 3 valuation measures might help you decide. EQT's three-year median payout ratio to shareholders is 11%, which is quite low. This implies that the company is retaining 89% of its profits. So it looks like EQT is reinvesting profits heavily to grow its business, which shows in its earnings growth. Moreover, EQT is determined to keep sharing its profits with shareholders which we infer from its long history of paying a dividend for at least ten years. Upon studying the latest analysts' consensus data, we found that the company's future payout ratio is expected to rise to 16% over the next three years. Regardless, the future ROE for EQT is speculated to rise to 11% despite the anticipated increase in the payout ratio. There could probably be other factors that could be driving the future growth in the ROE. Overall, we feel that EQT certainly does have some positive factors to consider. With a high rate of reinvestment, albeit at a low ROE, the company has managed to see a considerable growth in its earnings. That being so, a study of the latest analyst forecasts show that the company is expected to see a slowdown in its future earnings growth. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
